These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 11902578)

  • 21. TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe.
    Tanière P; Martel-Planche G; Saurin JC; Lombard-Bohas C; Berger F; Scoazec JY; Hainaut P
    Br J Cancer; 2001 Sep; 85(5):721-6. PubMed ID: 11531258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P53 family activities in development and cancer: relationship to melanocyte and keratinocyte carcinogenesis.
    Johnson J; Lagowski J; Sundberg A; Kulesz-Martin M
    J Invest Dermatol; 2005 Nov; 125(5):857-64. PubMed ID: 16297181
    [No Abstract]   [Full Text] [Related]  

  • 23. Contribution of p53, p63, and p73 to the developmental diseases and cancer.
    Tomkova K; Tomka M; Zajac V
    Neoplasma; 2008; 55(3):177-81. PubMed ID: 18348649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.
    Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y
    Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutation analysis of P73 and TP53 in Merkel cell carcinoma.
    Van Gele M; Kaghad M; Leonard JH; Van Roy N; Naeyaert JM; Geerts ML; Van Belle S; Cocquyt V; Bridge J; Sciot R; De Wolf-Peeters C; De Paepe A; Caput D; Speleman F
    Br J Cancer; 2000 Feb; 82(4):823-6. PubMed ID: 10732753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
    Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
    Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline mutations in the TP53 gene.
    Eeles RA
    Cancer Surv; 1995; 25():101-24. PubMed ID: 8718514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour-suppressor genes. Killer in search of a motive?
    Clurman B; Groudine M
    Nature; 1997 Sep; 389(6647):122-3. PubMed ID: 9296483
    [No Abstract]   [Full Text] [Related]  

  • 29. [An overview of research on p53 tumor suppressor gene].
    Yokozaki H; Tahara E
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2181-6. PubMed ID: 9422058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report.
    Anensen N; Skavland J; Stapnes C; Ryningen A; Børresen-Dale AL; Gjertsen BT; Bruserud Ø
    Leukemia; 2006 Apr; 20(4):734-6. PubMed ID: 16437140
    [No Abstract]   [Full Text] [Related]  

  • 31. Splitting p63.
    van Bokhoven H; Brunner HG
    Am J Hum Genet; 2002 Jul; 71(1):1-13. PubMed ID: 12037717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular strategies in Metazoan genomic evolution.
    Saccone C; Barome PO; D'Erchia AM; D'Errico I; Pesole G; Sbisà E; Tullo A
    Gene; 2002 Oct; 300(1-2):195-201. PubMed ID: 12468101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Cutaneous Leiomyosarcoma Arising in a Patient With Li-Fraumeni Syndrome: A Neoplasm With Unusual Histopathologic Features and Loss of Heterozygosity at TP53 Gene.
    Sabater-Marco V; Ferrando-Roca F; Morera-Faet A; García-García JA; Bosch SB; López-Guerrero JA
    Am J Dermatopathol; 2018 Mar; 40(3):225-227. PubMed ID: 28475508
    [No Abstract]   [Full Text] [Related]  

  • 34. The p53 tumor suppressor protein: meeting review.
    Prives C; Manfredi JJ
    Genes Dev; 1993 Apr; 7(4):529-34. PubMed ID: 8096197
    [No Abstract]   [Full Text] [Related]  

  • 35. Novel human pathological mutations. Gene symbol: TP53. Disease: Li-Fraumeni syndrome.
    Saxena R; Kohli S; Guleria K; Verma IC
    Hum Genet; 2010 Apr; 127(4):480. PubMed ID: 21488255
    [No Abstract]   [Full Text] [Related]  

  • 36. UREB1, a tyrosine phosphorylated nuclear protein, inhibits p53 transactivation.
    Gu J; Dubner R; Fornace AJ; Iadarola MJ
    Oncogene; 1995 Nov; 11(10):2175-8. PubMed ID: 7478539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolated ectrodactyly caused by a heterozygous missense mutation in the transactivation domain of TP63.
    Zenteno JC; Berdón-Zapata V; Kofman-Alfaro S; Mutchinick OM
    Am J Med Genet A; 2005 Apr; 134A(1):74-6. PubMed ID: 15736220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovca1, a candidate gene of the genetic modifier of Tp53, Mop2, affects mouse embryonic lethality.
    Liang M; Ayanga B; Du S; Godwin AK; Hartsock JK; Evans SC
    Genes Chromosomes Cancer; 2008 Apr; 47(4):315-25. PubMed ID: 18181179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The p53 family: prospect for cancer gene therapy.
    Zhang J; Chen X
    Cancer Biol Ther; 2007 Jan; 6(1):116-8. PubMed ID: 17612008
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeting p53 as a promising therapeutic option for cancer by re-activating the wt or mutant p53's tumor suppression.
    Węsierska-Gądek J
    Future Med Chem; 2018 Apr; 10(7):755-777. PubMed ID: 29569948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.